Layth Mula-Hussain: New Systematic Review Highlights NSCLC Molecular Markers in MENA Patients
Layth Mula-Hussain, Radiation Oncologist at BC Cancer, shared a post by Abdulaziz AlJassim, Thoracic and Sarcoma Medical Oncologist at The Ottawa Hospital, on X about a paper he and his colleagues authored published on Journal of Immunotherapy and Precision Oncology:
“Delighted to be part of this important research work that is needed in our MENA region about molecular markers in lung cancer. Thank you Dr. Abdulaziz AlJassim, for your insights and leadership.”
Quoting Abdulaziz AlJassim‘s post:
“Proud to share our GCC Lung Oncology Group publication in JIPO Editors
A systematic review + expert opinion on NSCLC in the MENA region highlights the prevalence of driver mutations in NSCLC across the MENA region EGFR 24% | ALK 7.9% | KRAS 19.7% This work underscores the importance of region-specific strategies.”
Title: Prevalence of Molecular Mutations in Non–Small Cell Lung Cancer and Current Treatment Approaches in the MENA Region: Systematic Review and Expert Opinion
Authors: AbdulAziz AlJassim, Aladdin Kanbour, Fathi Azribi, Muath AlNassar, Riadh Mohsen, Sahar Dawod, Selvaraj Giri, Michael Nasr Kamal, Ali AlJabban, Layth Mula-Hussain, Bader Alshamsan, Emad Anwar
Read the full article.
More posts featuring Layth Mula-Hussain on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023